Neogen Expands Availability of Prozap Products
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Neogen Corporation announced the expanded availability of FIFRA Section 2(ee) recommendations for the use of Prozap Insectrin X Concentrate and Prozap Screw Worm and Ear Tick Aerosol as part of New World Screwworm response efforts. These recommendations provide ranchers, livestock producers, and horse owners with an additional option to support fly management efforts. In Texas, the Texas Department of Agriculture has approved Section 2(ee) recommendations for these products. Neogen is also making Section 2(ee) recommendations available in Florida, providing producers in both states with additional tools to incorporate into broader fly management programs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NEOG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NEOG
Wall Street analysts forecast NEOG stock price to fall
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 8.930
Low
6.50
Averages
8.17
High
10.00
Current: 8.930
Low
6.50
Averages
8.17
High
10.00
About NEOG
Neogen Corporation and subsidiaries are engaged in developing, manufacturing and marketing a diverse line of products and services dedicated to food and animal safety. The Company has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. Its segments include Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors. This segment also provides genomic identification and related interpretive bioinformatic services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Neogen Corp Reports Food Safety Growth Amid Challenges
- Food Safety Revenue Growth: Neogen Corp's Food Safety segment achieved a 4% core revenue increase to $156.7 million, driven by strong performance in indicator testing and culture media products, thereby solidifying its market leadership.
- Adjusted EBITDA Improvement: The company reported adjusted EBITDA of $48.2 million with a margin of 22.8%, reaching one of the highest levels in recent history through stringent cost control, indicating significant operational efficiency gains.
- Animal Safety Segment Challenges: Despite strong food safety results, the Animal Safety segment experienced an 8.7% core revenue decline due to supply chain disruptions and rising transportation costs, impacting overall profitability.
- Future Outlook and Investment: Neogen plans to invest in R&D for its PetriFilm product line to accelerate innovation and create new growth opportunities, while anticipating continued supply chain challenges in the upcoming quarters.
See More
Neogen Shares Plummet Despite Increased Guidance and Strong Earnings Report.
- Fiscal-Year Outlook: Neogen increased its fiscal-year outlook despite reporting lower quarterly revenue.
- Net Loss: The company experienced a wider net loss during the same period.
See More
Neogen Reports Wider Q3 Net Loss of $17 Million
- Wider Net Loss: Neogen reported a net loss of $17 million for Q3, translating to $0.08 per share, which is an increase from a loss of $10.9 million or $0.05 per share in the same quarter last year, indicating heightened financial pressure on the company.
- Decline in Adjusted Earnings: The adjusted earnings per share fell to $0.09, down from $0.10 in the prior-year quarter, reflecting a weakening profitability that could impact investor confidence moving forward.
- Total Revenue Decline: Total revenue for the quarter decreased by 4.4% to $211.20 million, down from $221.0 million year-over-year, highlighting soft market demand that may pose challenges for future performance.
- Upward Revenue Guidance: The company has raised its revenue guidance for fiscal 2026 to between $857 million and $860 million, up from the previous range of $845 million to $855 million, indicating management's increased confidence in future growth prospects.
See More
NEOGEN CORP FY2026 Revenue Projection at $850.6 Million, According to LSEG IBES Data
- Company Overview: Neogen Corp is projected to generate $850.6 million in revenue by 2026.
- Market Position: The company is positioned as a significant player in the life sciences and food safety sectors.
See More
Neogen Q3 Earnings Beat Expectations
- Earnings Performance: Neogen's Q3 non-GAAP EPS of $0.09 exceeded expectations by $0.04, demonstrating resilience in profitability despite a decline in overall revenue.
- Revenue Analysis: The company reported Q3 revenue of $211.2 million, down 4.4% year-over-year, yet it surpassed market expectations by $6.58 million, indicating stable performance in the food safety segment.
- Divergent Business Growth: Food Safety revenue grew by 2.6% with core growth at 4.0%, while Animal Safety revenue plummeted by 20.1% with core growth at -8.7%, primarily due to challenges from third-party suppliers, reflecting the complexities of the market environment.
- Updated Financial Guidance: Neogen updated its FY26 financial guidance, projecting revenue between $857 million and $860 million, exceeding the $850.87 million consensus, showcasing management's confidence in future growth.
See More
NEOGEN REPORTS ADJUSTED NET INCOME OF USD 19.4 MILLION FOR Q3
- Financial Performance: NeoGen reported an adjusted net income of USD 19.4 million for Q3.
- Quarterly Results: The financial results indicate a significant performance metric for the company in the third quarter.
See More
Neogen Corp Reports Food Safety Growth Amid Challenges
- Food Safety Revenue Growth: Neogen Corp's Food Safety segment achieved a 4% core revenue increase to $156.7 million, driven by strong performance in indicator testing and culture media products, thereby solidifying its market leadership.
- Adjusted EBITDA Improvement: The company reported adjusted EBITDA of $48.2 million with a margin of 22.8%, reaching one of the highest levels in recent history through stringent cost control, indicating significant operational efficiency gains.
- Animal Safety Segment Challenges: Despite strong food safety results, the Animal Safety segment experienced an 8.7% core revenue decline due to supply chain disruptions and rising transportation costs, impacting overall profitability.
- Future Outlook and Investment: Neogen plans to invest in R&D for its PetriFilm product line to accelerate innovation and create new growth opportunities, while anticipating continued supply chain challenges in the upcoming quarters.
See More
Neogen Shares Plummet Despite Increased Guidance and Strong Earnings Report.
- Fiscal-Year Outlook: Neogen increased its fiscal-year outlook despite reporting lower quarterly revenue.
- Net Loss: The company experienced a wider net loss during the same period.
See More
Neogen Reports Wider Q3 Net Loss of $17 Million
- Wider Net Loss: Neogen reported a net loss of $17 million for Q3, translating to $0.08 per share, which is an increase from a loss of $10.9 million or $0.05 per share in the same quarter last year, indicating heightened financial pressure on the company.
- Decline in Adjusted Earnings: The adjusted earnings per share fell to $0.09, down from $0.10 in the prior-year quarter, reflecting a weakening profitability that could impact investor confidence moving forward.
- Total Revenue Decline: Total revenue for the quarter decreased by 4.4% to $211.20 million, down from $221.0 million year-over-year, highlighting soft market demand that may pose challenges for future performance.
- Upward Revenue Guidance: The company has raised its revenue guidance for fiscal 2026 to between $857 million and $860 million, up from the previous range of $845 million to $855 million, indicating management's increased confidence in future growth prospects.
See More
NEOGEN CORP FY2026 Revenue Projection at $850.6 Million, According to LSEG IBES Data
- Company Overview: Neogen Corp is projected to generate $850.6 million in revenue by 2026.
- Market Position: The company is positioned as a significant player in the life sciences and food safety sectors.
See More
Neogen Q3 Earnings Beat Expectations
- Earnings Performance: Neogen's Q3 non-GAAP EPS of $0.09 exceeded expectations by $0.04, demonstrating resilience in profitability despite a decline in overall revenue.
- Revenue Analysis: The company reported Q3 revenue of $211.2 million, down 4.4% year-over-year, yet it surpassed market expectations by $6.58 million, indicating stable performance in the food safety segment.
- Divergent Business Growth: Food Safety revenue grew by 2.6% with core growth at 4.0%, while Animal Safety revenue plummeted by 20.1% with core growth at -8.7%, primarily due to challenges from third-party suppliers, reflecting the complexities of the market environment.
- Updated Financial Guidance: Neogen updated its FY26 financial guidance, projecting revenue between $857 million and $860 million, exceeding the $850.87 million consensus, showcasing management's confidence in future growth.
See More
NEOGEN REPORTS ADJUSTED NET INCOME OF USD 19.4 MILLION FOR Q3
- Financial Performance: NeoGen reported an adjusted net income of USD 19.4 million for Q3.
- Quarterly Results: The financial results indicate a significant performance metric for the company in the third quarter.
See More
